(Q37634509)

21 August 2017

1 reference

title

Treatment of HIV infection: Swedish recommendations 2009. (English)

1 reference

21 August 2017

0 references

0 references

Lars Navér

7

0 references

Jan Albert

2

object named as

Jan Albert

1 reference

21 August 2017

Filip Josephson

1

1 reference

21 August 2017

Leo Flamholc

3

1 reference

21 August 2017

Magnus Gisslén

4

1 reference

21 August 2017

Olof Karlström

5

1 reference

21 August 2017

Lars Moberg

6

1 reference

21 August 2017

Veronica Svedhem

8

1 reference

21 August 2017

Bo Svennerholm

9

1 reference

21 August 2017

Anders Sönnerborg

10

1 reference

21 August 2017

Swedish Medical Products Agency

11

1 reference

21 August 2017

Swedish Reference Group for Antiviral Therapy

12

1 reference

21 August 2017

publication date

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

41

1 reference

21 August 2017

issue

11-12

1 reference

21 August 2017

page(s)

788-807

1 reference

Changes in the risk of death after HIV seroconversion compared with mortality in the general population

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Counselling gay men with multiple loss and survival problems: the bereavement group as a transitional object

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Lactic acidosis in HIV infected patients: a systematic review of published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Influence of HIV co-infection on hepatitis C immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

Current CD4 Cell Count and the Short‐Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIV‐Infected Children and Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903214322

10.3109/00365540903214322

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference